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Abstract
Ischemic cardiomyopathy, disease of the heart muscle due to coronary artery disease, is the 
most common cardiomyopathy. It is often difficult to discern the etiology of heart failure, 
and often there are multiple underlying causes. Ischemic cardiomyopathy most often pres-
ents with a dilated morphology with wall motion defects and a history of previous myocar-
dial infarction or confirmed coronary artery disease. Mechanisms of myocardial depression 
in ischemia are necrosis of myocardial cells resulting in irreversible loss of function or 
reversible damage, either short term through myocardial stunning or long term through 
hibernation. In ischemic cardiomyopathy, echocardiography may be extended with stress 
testing or other imaging modalities such as myocardial scintigraphy and cardiac magnetic 
resonance tomography. Coronary angiography is often considered a gold standard; how-
ever, other modalities such as positron emission tomography can be needed to detect small 
vessel disease. Cardiac revascularization, through percutaneous coronary intervention and 
coronary artery bypass grafting, both in acute coronary syndrome and in stable coronary 
artery disease, relieves symptoms and improves prognosis. Therapy should aspire to treat 
ischemia, arrhythmias in addition to heart failure management, which includes device 
therapy with cardiac resynchronization therapy, implantable cardioverter defibrillators, 
and mechanical support as bridging or destination therapy in end-stage disease.
Keywords: cardiomyopathy, coronary artery disease, heart failure, ischemic, 
myocardial infarction
1. Introduction
Disease of the heart muscle, cardiomyopathy, appears in various disease manifestations, 
which are often either poorly defined or difficult to distinguish in clinical practice. Despite 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
these shortcomings, it is important to determine the underlying etiology of cardiomyopathy, 
both for evidenced-based clinical practice and for research purposes. This chapter offers a 
definition of ischemic cardiomyopathy, the most common form of heart failure, as well as 
describes its epidemiology, pathophysiology, diagnosis, evaluation, and treatment. It aims 
to facilitate for clinicians who treat patients with ischemic cardiomyopathy, researchers, and 
other professionals with an interest in the field and also patients and their relatives.
1.1. Definition
The term ischemic cardiomyopathy describes a state of left ventricular systolic dysfunction 
due to coronary artery disease [1]. However, both European and American guidelines refer 
to the concept of cardiomyopathy as a primary heart muscle disease rather than the acquired 
forms of heart disease [2, 3]. Clinically, and for definitions in numerous scientific studies, 
patients with heart failure attributed to ischemic etiology are labeled as having ischemic 
cardiomyopathy. Thus, a heart failure patient with a history of myocardial infarction and 
evidence of coronary artery disease from imaging tools or functional tests is said to have 
an ischemic etiology. In practice, the etiology in an individual patient is not always clearly 
discernable. Patients with heart failure and no coronary artery disease may have angina/wall 
motion abnormalities [4]. On the other hand, severe coronary artery disease does not neces-
sarily imply symptoms, myocardial infarction, or heart failure [1]. Even with information 
from an invasive coronary angiography when evaluating heart failure, the etiology is not 
always unambiguous. In science, the same overlap between an ischemic cause and other con-
tributing causes frequently occur; heart failure may be complicated by hypertension, diabetes 
mellitus, valvular disease, and other factors that may interplay [5]. Nevertheless, it is impor-
tant to interpret subgroup analyses with this in mind as it may explain inconsistency between 
studies. It has been proposed that patients with single-vessel disease should be classified as 
having nonischemic cardiomyopathy [1]. Typically, patients with ischemic cardiomyopathy 
include those with reduced ejection fraction with a cutoff at 35–40%, although this is also 
somewhat arbitrary [1, 6]. The boundaries between ischemic, nonischemic, and mixed dilated 
cardiomyopathy are worth taking into account depending on the context [7].
1.2. Epidemiology
Ischemic cardiomyopathy is common, and it is increasing worldwide based on risk fac-
tors for coronary artery disease becoming more prevalent. According to the World Health 
Organization (WHO), ischemic heart disease is considered the most common cause of death 
worldwide, and cardiovascular heart disease, which is predominantly coronary artery dis-
ease, claims a global death toll of 17.7 million every year, comprising 31% of all deaths [8]. 
More than three quarters of cardiovascular deaths come from low- and middle-income coun-
tries [9]. Furthermore, coronary artery disease is considered the most common cause of heart 
failure which affects 1–2% of the general population and 10% of people aged 70 years or more 
[10]. The risk of having heart failure diagnosed during the remaining lifetime at an age of 
55 years is higher for men (33%) than women (28%) [11]. Etiological causes of heart failure 
are diverse, but the ischemic component is considered to be the largest contributor. Ischemic 
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heart disease includes myocardial scar, stunning/hibernating myocardium, epicardial coro-
nary artery disease, abnormal coronary microcirculation, and endothelial dysfunction [6]. The 
incidence of ischemic cardiomyopathy is likely to increase globally over the coming decades.
1.3. Pathophysiology
The pathophysiology consists of two major mechanisms: reversible and irreversible damage of 
the myocardium that results in reduced myocardial function and cardiac output, with progres-
sion into a dilated phase. This myocardial damage is typically caused mainly by atherosclerosis 
of coronary arteries that result in reduced perfusion of cardiac muscle tissue, which clinically 
presents as acute coronary syndromes: ST-segment elevation myocardial infarction (STEMI), 
non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina pectoris. 
Both STEMI and NSTEMI are characterized by the presence of necrosis of the myocardium 
and elevated cardiac biomarkers, whereas unstable angina is characterized by myocardial isch-
emia without necrosis of myocardial cells; however, all forms of myocardial ischemia can cause 
impaired myocardial function and ischemic cardiomyopathy. Prompt revascularization restores 
parts of viable myocardium, whereas other parts undergo necrosis and are thus irreversibly 
damaged. The transient myocardial depression during acute coronary syndrome is referred as 
stunning. Long-lasting but potentially reversible ischemic depression is described as hibernat-
ing myocardium. Hibernation and stunning are interchangeable when it occurs from repetitive 
temporary ischemic triggers [12]. This is important to recognize as triggers may be managed, 
and successful revascularization in conjunction with an optimal pharmaceutical approach may 
improve ejection fraction. From this perspective ischemic cardiomyopathy is a dynamic disease. 
It does not necessarily lead to deterioration and clinical improvement is possible. Occlusion of 
a coronary artery causes a localized myocardial injury in areas of reduced perfusion, whereas 
global coronary artery disease may lead to diffuse myocardial injury. Both global and localized 
myocardial impairments constitute components of ischemic cardiomyopathy.
1.3.1. Coronary artery disease
Coronary artery disease is a consequence of atherosclerosis, which is attributed to many risk 
factors. Increasing age and male sex independently imply higher risk. The majority of risk fac-
tors are modifiable. In the international study INTERHEART, several risk factors for myocar-
dial infarction were identified [13]. In this study, moderate amount of alcohol was beneficial, 
especially in women, but these results should be interpreted with caution:
• ApoB/ApoA1 ratio
• Smoking
• Diabetes mellitus
• Physical inactivity
• Psychosocial risk factors
• Abdominal obesity
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• Hypertension
• Diet (less fruit/vegetables)
There is a strong age-related increase of atherosclerosis and myocardial infarction. 
Approximately 4% of the population, aged 75–84 years, suffers from symptomatic coronary 
disease [14]. There is a strong link between angina and risk of coronary artery disease mor-
tality on a group level [14, 15]. Hypertension has been demonstrated to be causally linked to 
coronary artery disease [16]. Hypercholesterolemia is a major pathway to manifest coronary 
disease, and clinical events have been shown in this group in several studies over decades 
[16–19]. Diabetic patients have an approximately threefold risk of myocardial infarction 
based on increased risk of coronary artery disease [20]. Smoking is a risk factor because of 
its vascular damaging effects [21]. Obesity and lifestyle factors, such as physical inactivity, 
also constitute risk factors [22]. Family history is complex but is an independent risk factor 
for coronary artery disease [23]. These factors, often in combination, may lead to multivessel 
disease; ischemic cardiomyopathy patients have more proximal locations of stenoses, greater 
lumen loss lesions and thus more extensive ischemic burden, and severe clinical manifesta-
tion with reduced working capacity [24].
2. Symptoms and signs
Ischemic cardiomyopathy patients present with the same general symptoms that are com-
mon in heart failure regardless of etiology. Typical symptoms of ischemic cardiomyopathy are 
breathlessness, orthopnea, exercise intolerance, fatigue, ankle swelling, less typically noctur-
nal cough, wheezing, bloated feeling, loss of appetite, confusion, palpitations, dizziness, and 
syncope. Symptoms are often accompanied by signs such as elevated jugular venous pressure, 
hepatojugular reflux, third heart sound (gallop rhythm), and laterally apical chamber impulse. 
There may also be less specific signs: weight gain due to fluid retention but also weight loss 
and cachexia in advanced heart failure, hepatomegaly, ascites, cold extremities, oliguria, and 
crepitations at pulmonary auscultation [6]. The first presentation might be as acute coronary 
syndrome, arrhythmias (atrial/ventricular tachycardia or bradycardia), or thromboembolic 
complications of left ventricular thrombus/atrial fibrillation after myocardial infarction such 
as stroke or systemic thromboembolism. Psychiatric symptoms such as depression and anxi-
ety are common as a consequence of the mentioned symptoms and signs [25].
2.1. NYHA functional classification
The New York Heart Association (NYHA) Functional Classification is frequently used to clas-
sify heart failure into four categories according to the severity of symptoms [26]:
• NYHA Class I: asymptomatic.
No limitation in physical activity despite the presence of heart disease. This can be sus-
pected only if there is a history of heart disease, which is confirmed by investigations, for 
example, echocardiography.
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• NYHA Class II: mild.
Slight limitation in physical activity, more strenuous activity, causes shortness of breath, 
for example, walking on steep inclines or several flights of steps. Patients in this group can 
continue to have an almost normal lifestyle and employment.
• NYHA Class III: moderate.
More marked limitation of activity that interferes with work. Walking on flat ground pro-
duces symptoms.
• NYHA Class IV: severe.
Unable to carry out any physical activity without symptoms, patients are breathless at rest 
and mostly housebound [26].
3. Diagnosis
History taking and physical examination remain important, but laboratory tests and cardiac 
imaging are today a key part of diagnosis and management of ischemic cardiomyopathy.
3.1. History
Assessment of risk factors for atherosclerosis and cardiovascular disease is an important part 
of the history and can support clinicians by enabling the classification of patients into three 
categories, low-, intermediate-, and high-risk groups, and thus aid in the selection of appropri-
ate testing and treatment to minimize risk. According to American guidelines for assessment 
of cardiovascular risk, global risk scores (such as the Framingham Risk Score) that use mul-
tiple traditional cardiovascular risk factors should be obtained for risk assessment in asymp-
tomatic adults without a clinical history of cardiovascular disease. These scores are useful for 
combining individual risk factor measurements into a single quantitative estimate of risk that 
can be used to target preventive interventions [27, 28]. Framingham Risk Score is an algorithm 
used in assessment of 10-year cardiovascular risk and is based on data that was obtained from 
the Framingham Heart Study, which is a study on the residents of the city of Framingham, 
Massachusetts, that began in 1948 [27, 28]. The predictors used in the Framingham Heart study 
are age, sex, diabetes mellitus, smoking, treated and untreated systolic blood pressure, total 
cholesterol, high-density lipoprotein (HDL) cholesterol, and body mass index (BMI) replacing 
lipids in a simplified model [30]. Moreover, familial history of coronary artery disease should 
be investigated to assess the risk of ischemic heart disease in asymptomatic individuals [27, 28]. 
This assessment of risk factors and classification of risk groups determine the next step of inves-
tigations and treatment; for example, low risk patients do not need further investigations for 
risk evaluation. On the other hand, intensive preventive interventions are already indicated in 
high-risk patients, and thus further testing or risk assessment would not give additional benefit 
[27]. Other manifestations of atherosclerosis such as stroke, carotid artery disease, and inter-
mittent claudication are signs of increased risk for ischemic heart disease because atheroscle-
rosis is generalized and can affect any part of the vasculature [29]. History taking should also 
include questions about symptoms that indicate the presence of ischemic heart disease, such as 
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retrosternal chest pain or discomfort that indicates angina, and this is often described as squeez-
ing, burning pain or as a pressure, tightness, fullness, or a heavy weight in the middle of the 
chest that extends to the neck, left arm, jaw, and back. These symptoms can be accompanied by 
sweating, nausea, and vomiting [30]. Angina itself can be stable or unstable angina, and unsta-
ble angina comes in many different forms according to the American Heart Association [31]:
• Rest angina within 1 week of presentation.
• New-onset angina of the Canadian Cardiovascular Society (CCS) classification grade III or 
IV within 2 months of presentation.
• Angina increasing in CCS grade to at least grade III or IV.
• Variant angina.
• Non-Q-wave myocardial infarction.
• Post-myocardial infarction angina (>24 hours).
Canadian Cardiovascular Society (CCS) grading of angina pectoris is a practical way to define 
severity of angina by the level of physical activity needed for symptoms to arise (Table 1) [30].
3.2. Physical examination
Physical examination is of value in the assessment of a patient with suspected ischemic 
cardiomyopathy and grants important information. Heart murmurs and sounds might indi-
cate valvular disease or other hemodynamic defects. Swelling of the ankles, an enlarged 
liver, crepitations on lung auscultation, and tachycardia can be signs of congestive heart 
failure [32]. Signs of atherosclerosis risk factors can predict the presence of coronary artery 
disease, for example, abdominal obesity and xanthelasma that is often associated with 
hyperlipidemia.
Blood pressure might be elevated, which is a risk factor for atherosclerosis and myocardial 
infarction, or it might be low, which could indicate hemodynamic compromise because 
of decreased cardiac output in severe heart failure. According to the American College of 
Cardiology guidelines from 2017, blood pressure is classified as normal, elevated, stage 1, or 
stage 2 hypertension (Table 2) [31].
Grade Activity evoking angina Limits to normal activity
I Prolonged exertion None
II Walking >2 blocks Slight
III Walking ≤2 blocks Marked
IV Minimal or rest Severe
Table 1. Canadian Cardiovascular Society grading of angina pectoris.
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3.3. Resting electrocardiography
A 12-lead electrocardiography (ECG) is simple, easily accessible, cheap, and noninvasive as 
well as an important tool in the management of ischemic cardiomyopathy. It is recommended 
that a 12-lead ECG is performed in patients with hypertension or diabetes mellitus even if no 
symptoms are present. Additionally, in patients without these risk factors and without symp-
toms, it may still be of value [27].
Myocardial ischemia may present with different changes on ECG, and these changes may 
appear temporarily during acute myocardial ischemia (e.g., ST-segment elevations) or remain 
permanently such as pathological Q-waves after a transmural infarction:
• ST-segment morphology changes [33]. ST-segment elevation occurs in acute STEMI, 
whereas ST-segment depression occurs in NSTEMI or unstable angina.
• T-wave morphology changes. The T-wave becomes upright and tall, coronary T-waves, in 
the first few minutes of myocardial infarction (STEMI) or may be become inverted/negative 
in NSTEMI and unstable angina.
• Pathological Q-waves which are negative and deep appear on ECG in transmural myocar-
dial infarction and remain as a sign of permanent damage [33].
• Tachyarrhythmias such as ventricular tachycardia and ventricular fibrillation or bradyar-
rhythmia such as atrioventricular block degrees I–III.
• New left bundle branch block and less commonly right bundle branch block.
ECG abnormities may provide clues for the diagnosis of ischemic cardiomyopathy but have 
low specificity [34]. ECG signs can guide therapy. If atrial fibrillation is present, lifelong 
oral anticoagulation is warranted since all patients with ischemic cardiomyopathy and atrial 
fibrillation are at risk of thromboembolism. Symptomatic sinus node dysfunction or high-
degree atrioventricular block can necessitate permanent pacemaker, except for intermit-
tently during the acute phase of STEMI/NSTEMI because bradyarrhythmia is often transient 
following myocardial infarction. In ischemic cardiomyopathy patients with bundle branch 
block, typically left, cardiac resynchronization therapy (CRT) can be an option to improve 
symptoms of heart failure and survival. A completely normal ECG makes ischemic cardio-
myopathy unlikely.
Classification Blood pressure
Normal <120/<80 mmHg
Elevated 120–129/<80 mmHg
Hypertension stage 1 130–139 or 80–89 mmHg
Hypertension stage 2 ≥140 or ≥90 mmHg
Table 2. Blood pressure classification according to ACC guidelines 2017.
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3.4. Laboratory tests
Laboratory tests can reveal and quantify many risk factors for ischemic cardiomyopathy, such 
as diabetes mellitus, hypercholesterolemia, renal failure, and C-reactive protein (CRP) [35].
3.4.1. Creatine kinase-MB
Creatine kinase-MB (CK-MB) is a myocardial enzyme that is elevated in blood in cardiac 
muscle damage and ischemia, but it is not a specific marker for myocardial ischemia and can 
be elevated in other conditions, for example, renal failure, rhabdomyolysis, heart failure, and 
hypothyroidism [36, 37].
3.4.2. Troponins
Cardiac troponins are proteins that regulate the contraction of striated muscles and include 
three subunits (troponin C, troponin T, and troponin I) [38]. Cardiac troponin T and troponin 
I are cardiac regulatory proteins that control the calcium-mediated interaction between actin 
and myosin [39]. Cardiac troponin C is also identified in skeletal muscles, and thus it is not 
specific for myocardial damage [37]. The elevation of serum levels of cardiac troponins (T, I) 
is used in the diagnosis of acute myocardial infarction as a biochemical marker [39, 40]. They 
are superior compared to CK-MB as biomarkers for detection of the myocardial damage that 
is associated with myocardial infarction, and moreover, while levels are affected by renal 
function, they still have a reliable predictive value in patients with acute coronary syndrome 
regardless of renal function [41]. The raised cardiac troponin in serum may not be detectable 
for up to 4 hours after myocardial infarction; therefore, repeated tests should be performed 
again, for example, after 3 and 9 hours, if troponins were not raised on admission in patients 
with suspected acute coronary syndrome [39, 42]. Troponin I has a high specificity for myo-
cardial muscle injury. Troponin I has three isoforms: cardiac, skeletal slow twitch, and skel-
etal fast twitch [36, 37]. It does not increase in skeletal muscle diseases, after normal physical 
exercise or in hypothyroidism [36]. It is not detected in healthy individuals without acute 
coronary syndrome or another disease with damage to myocytes such as myocarditis [36, 
43]. Raised cardiac troponins have an important diagnostic and prognostic value in acute 
coronary syndrome, caused by atherosclerosis and occlusion of coronary arteries (primary 
myocardial ischemia), but it can be detected in secondary myocardial ischemia associated 
with many other conditions such as cardiac arrhythmias, large pulmonary embolization, 
heart failure of other etiologies such as idiopathic dilated cardiomyopathy and hypertro-
phic cardiomyopathy, or after therapeutic procedures, for example, coronary intervention 
(angioplasty), vasospastic angina, electrophysiological ablations, or electrical cardioversions 
[38, 39]. Furthermore, raised cardiac troponins can be caused by nonischemic myocardial 
damage in conditions such as perimyocarditis, cardiac trauma, septicemia, and chemother-
apy [39]. In addition, cardiac troponins are raised in patients with renal failure without acute 
coronary syndrome, and the exact mechanism of this increase of cardiac troponin levels is 
still unclear, although raised cardiac troponin I in individuals with renal failure is contro-
versial [36, 37, 39]. It appears that elevated troponin in renal failure is not associated with 
myocardial infarction rather with chronic myocardial damage and depends upon the assay 
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technology [42]. However, cardiac troponins remain of predictive value in individuals with 
chest pain and suspected acute coronary syndrome despite renal failure [39]. Cardiovascular 
death is common in end-stage renal disease, and both increased cardiac troponin I and T 
predict a two- to fivefold increase in mortality in these patients [41].
3.4.3. B-type natriuretic peptide
B-Type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) are secreted by 
ventricular cardiomyocytes as a result of stress and tension in the muscle fibers of the ven-
tricular wall and by myocardial ischemia. They have a strong prognostic and diagnostic value 
in patients with heart failure. Both BNP and NT-proBNP are significantly elevated in indi-
viduals with systolic or diastolic myocardial dysfunction. High levels are predictive of worse 
prognosis and higher risk of cardiovascular death and readmission to hospital. Furthermore, 
BNP and NT-proBNP levels indicate the severity of heart failure [44]. Until recently, the clini-
cal application of BNP and NT-proBNP measurement in patients with coronary artery disease 
has been unclear, but many recent studies have found that both BNP and NT-proBNP levels 
increase in myocardial ischemia and acute coronary syndromes. This has led to the sugges-
tion that these biomarkers can be secreted by cardiomyocytes as a direct result of myocardial 
ischemia regardless of ventricular wall stress [44, 45]. In support of this, it has been found that 
transient myocardial ischemia that occurs due to coronary interventions (stent inflation) can 
lead to elevation of BNP levels [46]. However, the diagnostic and prognostic value of these 
biomarkers in coronary artery disease remains unclear, and further investigations are needed.
3.5. Cardiac imaging
Cardiac imaging is an essential tool in understanding heart failure and guiding treatment. 
Historically, X-ray played a role to show pulmonary congestion and may add other clues to 
a dyspnea investigation. Instead, today echocardiography is the cornerstone in management 
of heart failure. It provides information about the morphology of all four chambers, function 
of wall motion and valves, ejection fraction, pulmonary artery pressure, and pericardial effu-
sion, and is available, noninvasive, and cheap. Other imaging methods are used in the evalua-
tion and provide incremental value, some are an essential part of clinical practice, and others 
are mainly used in research, but this may change in the future.
3.5.1. Transthoracic echocardiogram
Transthoracic echocardiography includes two- and three-dimensional techniques, pulsed 
and continuous Doppler, color Doppler, tissue Doppler imaging and contrast, and strain 
measurements. Assessment of ejection fraction is important as it guides therapeutic choices 
with regard to pharmaceutical agents and device therapy and provides information about 
prognosis. Therefore the method used to determine ejection fraction is crucial. According to 
ESC guidelines, Simpson’s rule is the preferred choice. It should be obtained from the apical 
four-chamber view and two-chamber view but requires accurate tracing of the endocardium. 
Echocardiography is the most common diagnostic investigation for coronary artery disease 
after ECG and chest X-ray [47] and can provide detailed information about left ventricular 
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function, cardiac output, left ventricular ejection fraction, wall motion abnormalities in isch-
emic cardiomyopathy, and possible complications of acute coronary syndromes such as 
myocardial aneurysm [48], mitral regurgitation secondary to papillary muscle dysfunction 
or rupture [47, 49], intracardiac thrombus [50], ventricular free wall rupture, and pseudoa-
neurysm formation after myocardial infarction [47]. Transthoracic echocardiography is an 
important tool in the assessment of patients with acute chest pain, both for diagnosis of acute 
coronary syndromes and for exclusion of other causes of acute chest pain such as aortic dis-
section and pericardial effusion.
Echocardiogram findings in ischemic cardiomyopathy include:
• Decreased left ventricular ejection fraction, which is one of the most important predictors 
of mortality [51, 52].
• Left ventricular diastolic dysfunction [53]. The evaluation of left ventricular dysfunction 
and filling pressures is of great benefit to distinguish ischemic cardiomyopathy from other 
syndromes that cause dyspnea such as pulmonary diseases [54].
• Regional or diffuse wall motion abnormalities [53, 55].
• Mitral and tricuspid regurgitations [53].
• Detection of both localization and size of myocardial infarction [47].
According to 2013 ESC guidelines on the management of stable coronary artery disease, rest-
ing echocardiography should be performed in all patients with the first presentation of coro-
nary artery disease:
• Exclusion of alternate causes of angina.
• Identification of regional wall motion abnormalities suggestive of coronary artery disease.
• Measurement of left ventricular ejection fraction for risk stratification and quantification of 
heart failure severity.
• Evaluation of diastolic function [54].
3.5.2. Stress echocardiography
The principle of stress echocardiography is the combination of physical (treadmill or bicycle), 
pharmacological (dobutamine, dipyridamole, or adenosine), or electrical stress (external pac-
ing) with two-dimensional echocardiography [56]. The goal of this technique is the provoca-
tion of myocardial ischemia that can be detected with a two-dimensional echocardiogram. 
It is a noninvasive and easy test for both the patient and the physician and has accuracy in 
diagnosis of coronary artery disease comparable to that of radionuclide stress perfusion imag-
ing or cardiac magnetic resonance, but it is ultimately less expensive [57].
The response of the myocardium depending on regional wall function during stress echo-
cardiography can be classified into four patterns: normal, ischemic, necrotic, and viable [57].
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• Normal response: normokinetic wall function at rest and normo- or hyperkinetic at stress.
• Ischemic response: normokinetic regional wall function at rest and hypokinesia, akinesia, 
or dyskinesia at stress. Stress exacerbates wall dysfunction.
• Necrotic response: an area with wall dysfunction at rest stays immobile at stress.
• Viability response: an area with dysfunction at rest responds either with recovery and im-
provement at stress or with improvement at an early phase of stress and thereafter impair-
ment (biphasic response); this indicates viability despite ischemia.
A common indication for stress echocardiography is the diagnosis of coronary artery disease 
in the group of patients in whom exercise ECG is contraindicated, unfeasible, or not diag-
nostic [57, 58]. It can also be used in the assessment of viability in ischemic cardiomyopathy 
before revascularization. In addition, stress echocardiography can be used in the assessment 
of a patient with established coronary artery disease after revascularization, but also to evalu-
ate the preoperative risk in patients with coronary artery disease and too reveal the region of 
ischemia in the myocardium.
3.5.3. Coronary computed tomographic angiography
Computed tomography of the coronary arteries is an accurate noninvasive diagnostic test for 
coronary artery disease [59]. In addition, it provides information on cardiac valves and chambers 
[60]. The main practical application of computed tomography angiography has been in the out-
patient setting in patients with suspected coronary artery disease, but many studies now exam-
ine its application in the setting of low-risk chest pain patients in the emergency department [60]. 
The advantage of computed tomography angiography is its negative predictive value, while the 
method is lacking in positive predictive value (i.e., it is good at ruling out, but less good at con-
firming coronary artery disease) [60]. It should be considered in patients with lower risk of coro-
nary artery disease as an alternative to stress testing or when results have been inconclusive [55].
3.5.4. Nuclear imaging modalities
Myocardial scintigraphy, positron emission tomography (PET), and single photon emission 
computed tomography (SPECT) all utilize radioactive isotopes for imaging. Scintigraphy 
forms two-dimensional images, while images from PET and SPECT form images in three 
dimensions. Scintigraphy and SPECT utilize gamma cameras to detect gamma radiation, while 
PET simultaneously detects two gamma rays emitted at a 180° angle to each other. Cardiac 
nuclear imaging at rest gives information about areas damaged by myocardial infarction and 
myocardial viability by mapping metabolism and perfusion. Exercise or pharmacological 
(usually dobutamine) stress testing provides information on the presence of angina and low 
perfusion in coronary arteries resulting in ischemia. Importantly, measurement of perfusion 
by scintigraphy is relative (not absolute) to the area with the highest perfusion. Because of this 
relative expression of quantification, three-vessel coronary disease with equally reduced per-
fusion in the whole heart might appear to be well perfused. In cases where this relative perfu-
sion will be misleading, PET should be performed instead. The SHIFT trial viability substudy 
Ischemic Cardiomyopathy: Contemporary Clinical Management
http://dx.doi.org/10.5772/intechopen.76723
113
indicated that viability or absence thereof did not identify patients with more benefit from 
coronary artery bypass grafting [61]. However, decision-making about revascularization based 
on viability using imaging could be considered in special cases. Sympathetic innervation imag-
ing with specific tracers can be used in heart failure for risk stratification, although this is 
seldom used in clinical practice [62]. Stress testing is valuable in the evaluation of manifest or 
suspected coronary artery disease; however, it is mainly those who are unable to perform exer-
cise testing (treadmill or bicycle) or those with defects on resting ECG that make exercise ECG 
difficult to interpret (pacemaker rhythm/bundle branch block) that are in need of radionu-
clide imaging. Scintigraphy should also be considered in patients with high pretest probability 
of coronary artery disease as an alternative to exercise ECG. All nuclear imaging modalities 
expose the patient to a small, but not negligible, amount of ionizing radiation. PET and SPECT 
are further limited by comparatively high cost and limited accessibility (especially of PET trac-
ers because of short half-life time) and are not routinely used. PET can be used to measure 
regional myocardial blood flow, by comparing this at maximal hyperemia, and at resting flow, 
an estimation can be made of noninvasive fractional flow reserve. This otherwise requires an 
invasive coronary angiography to measure (decline in arterial pressure over a stenosis) [63].
3.5.5. Cardiac magnetic resonance tomography
The main advantage of magnetic resonance in the evaluation of ischemic cardiomyopathy 
is the ability to visualize scar tissue, which is nonviable and the remaining contractile myo-
cardial tissue which is viable. In this context, there are two modalities of cardiac magnetic 
resonance tomography: the modality first utilizes late gadolinium enhancement in the assess-
ment of nonviable tissue, and the second modality uses low-dose dobutamine stress magnetic 
resonance in the assessment of viable tissue [64]. The method assesses ventricular volumes, 
functions in addition to scar tissue, and is free of ionizing radiation; complications are rare 
and almost exclusively related to stress testing [65–67]. For patients with suspected coronary 
artery disease, normal cardiac magnetic resonance tomography is a predictor of good prog-
nosis with 1-year cumulative incidence of adverse events at 1.0% (all-cause mortality, aborted 
sudden cardiac death, myocardial infarction), which is comparable to the population at large 
[67]. Moreover, magnetic resonance has been shown to both detected ischemic cardiomyopa-
thy that was not previously suspected and conversely to find an alternate diagnosis in previ-
ously suspected coronary artery disease [65, 66].
3.5.6. Diagnostic invasive coronary angiography
Invasive coronary angiography is a procedure where a catheter is inserted into the coronary 
arteries, usually through the radial artery. By using radiocontrast and X-ray images, coronary 
vasculature can be assessed. Coronary angiography retains the advantage that if a stenosis or 
culprit lesion requiring intervention is found, it can be treated by balloon angioplasty and the 
insertion of a stent. Fractional flow reserve is a way of determining the physiological significance 
of a stenosis and is the ratio of blood pressure measured distally to and proximally to the steno-
sis; this is usually considered to be significant at 0.8 [68]. The purpose should be to either per-
form coronary angiography to treat confirmed coronary artery disease (percutaneous coronary 
Current Perspectives on Cardiomyopathies114
intervention) or to rule out stable coronary artery disease with noninvasive testing: Only if this 
has failed, a diagnostic coronary angiography should be considered [55]. Patients with severe 
angina (CCS 3) should perform coronary angiography, as well as patients with a clinical profile 
or noninvasive testing indicating high risk of cardiovascular death or myocardial infarction [55].
4. Treatment
Broadly speaking, the treatment of ischemic cardiomyopathy could be said to consist of four 
strategies: the primary and secondary prevention of coronary artery disease, anti-ischemic 
treatment such as revascularization and antiplatelet therapy, treatment of heart failure with 
medications or cardiac devices, and the prevention and treatment of arrhythmia and sudden 
cardiac death that often accompany ischemic cardiomyopathy.
4.1. Prevention of coronary artery disease
Physical activity, weight loss in patients with the metabolic syndrome or obesity, cessation of 
smoking, and treatment of hypertension, diabetes mellitus, and hypercholesterolemia (espe-
cially lowering of LDL) prevent progression of coronary artery disease and thus the develop-
ment or worsening of ischemic cardiomyopathy [69].
4.1.1. Statins
All individuals with coronary artery disease have high risk of cardiovascular events and 
should be treated with statins according to the recommendations of the ESC/European 
Atherosclerosis Society guidelines for the management of dyslipidemia, regardless of low-
density lipoprotein cholesterol (LDL-C) levels [70]. The goal of treatment is to reach LDL-C 
target <1.8 mmol/L and/or >50% reduction if it could not reach the target level [55]. Other 
medications (e.g., fibrates, resins, nicotinic acid, and ezetimibe) may reduce the LDL choles-
terol level without any benefit on clinical outcomes [55].
4.2. Anti-ischemic therapy
Ischemia is by definition the root cause of ischemic cardiomyopathy; thus, targeting this 
pathophysiological mechanism is of great importance for prevention and treatment. 
Revascularization should if possible be the first line of therapy in acute coronary syndrome. 
Antiplatelet therapy inhibits the formation of blood clots in coronary arteries, thereby decreas-
ing risk of myocardial infarction, while other medications increase vasodilation and coronary 
blood flow or decrease heart rate and myocardial oxygen demand.
4.2.1. Revascularization
In patients with ischemic cardiomyopathy, revascularization should always be considered 
in addition to optimal pharmacological treatment [71]. Revascularization can be performed 
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as open heart surgery, coronary bypass grafting, or percutaneous coronary intervention. The 
choice of method should be discussed with expertise in revascularization preferably including 
cardiothoracic surgery and anesthesiology in selected cases. In one study, all-cause mortality 
after 9.8 years was significantly lower in the coronary artery bypass graft group compared with 
patients in the medical therapy group (59 versus 66% [359 versus 398 patients]; hazard ratio 
0.84; 95% confidence interval 0.73–0.97). In the STICH trial, the following variables were associ-
ated with improved outcome after coronary artery bypass grafting: 6-minute walk test more 
than 300 m, three-vessel disease, mitral regurgitation, and ejection fraction less than 27% [72]. 
Median follow-up was 56 months, and it also significantly improved health-related quality of life 
(at 4, 12, 24, and 36 months as assessed by the Kansas City Cardiomyopathy Questionnaire) [73]. 
Most studies show improvement in both survival and ejection fraction after revascularization 
compared to optimal pharmacological therapy alone [74–76]. It seems like viable myocardium 
is a predictor of improved survival [75, 76]. Unfortunately, there are no randomized controlled 
trials comparing percutaneous coronary intervention and coronary artery bypass grafting in 
ischemic cardiomyopathy. In an observational study, death rates were similar at median follow-
up of 2.9 years. Patients who underwent percutaneous coronary intervention had larger risk of 
myocardial infarction and repeated revascularization but lower risk of stroke [77].
4.2.2. Antiplatelet and anticoagulant therapy
Antiplatelet drugs prevent occlusion by inhibiting platelet adhesion and thus the formation 
of thrombi in coronary vessels [78]. Acetylsalicylic acid is well studied, it exerts its effect by 
inhibiting cyclooxygenase (COX-1 and COX-2) enzymes and reduces cardiovascular death by 
15% in high-risk patients [79]. Low-dose acetylsalicylic acid therapy is essential in secondary 
prevention of cardiovascular events in coronary artery disease, and its benefit in this case is 
clear, but it is not recommended in the primary prevention of myocardial infarction [55, 79]. 
The P2Y
12
 receptor is a protein, which exists on the surface of platelets and plays an essential 
role in the aggregation process activated by adenosine diphosphate. In acute coronary syn-
drome, a P2Y
12
 antagonists such as clopidogrel, prasugrel, or ticagrelor is recommended in 
addition to acetylsalicylic acid; this treatment should be continued for up to 12 months in the 
case of revascularization with a stent [80]. A P2Y
12
 inhibitor can also be considered for sec-
ondary prevention when acetylsalicylic acid is unsuitable. In cases of primary percutaneous 
coronary intervention due to STEMI, dual antiplatelet therapy should be complemented with 
unfractionated heparin. A parenteral glycoprotein IIb/IIIa inhibitor, which inhibits platelet 
aggregation, may be considered as bailout therapy if thrombi or falling fractional flow reserve 
is seen during primary percutaneous coronary intervention [80]. In acute coronary syndrome 
without ST-segment elevation, a low-molecular-weight heparin, such as fondaparinux, 
should be administered subcutaneously [81].
4.2.3. Beta-blockers
Beta-blockers exert beneficial effects on the myocardium that decrease heart rate, contractility, 
atrioventricular conduction, and risk of arrhythmia. Beta-blockers reduce the risk for cardio-
vascular death and myocardial infarction by 30% in post-myocardial infarction patients and 
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are useful in the management of effort-induced angina [55, 82]. In Europe, the most widely 
used beta-blockers provide predominantly β
1
-blockade, such as bisoprolol, metoprolol, ateno-
lol, and nebivolol. Carvedilol, which is a nonselective β-blocker that targets the α
1
-receptor, is 
also used, especially in advanced heart failure. By decreasing heart rate and contractility, the 
oxygen demand of the heart muscle decreases, thus also decreasing ischemia and ventricular 
arrhythmia. However, beta-blockers might worsen prognosis in the context of bradycardia or 
circulatory shock, because of negative inotropic effects, and should be used with caution in 
heart failure with decompensation.
4.2.4. Ivabradine
Ivabradine is a blocker of the funny channel, I
f
, which is found almost exclusively in the sinus 
node. By selective inhibition of the sinus node, reduction of heart rate and minimization of 
myocardial oxygen demand can be achieved, without negative inotropic effect that could 
result in lowered blood pressure [55]. Ivabradine has been shown to improve heart failure 
outcomes both in ischemic and unspecific etiologies. It is indicated in patients with sinus 
rhythm above 70 beats per minute [83, 84]. The combination of atenolol with ivabradine 
7.5 mg twice daily gave better heart rate control and amelioration of angina symptoms [55].
4.2.5. Vasodilators
Calcium channel blockers play a role in the management of coronary artery disease by its 
main effect on vessels with vasodilation and lowering of peripheral vascular resistance. 
Calcium channel blockers are classified into two main groups: the dihydropyridines that 
include amlodipine, nifedipine, felodipine, lacidipine, and lercanidipine and the non-
dihydropyridines that include verapamil and diltiazem. Dihydropyridines have a greater 
vascular selectivity, whereas non-dihydropyridines have a property of nodal suppression 
and tendency of heart rate lowering, which is why the combination of beta-blockers and 
non-dihydropyridines (verapamil and diltiazem) must be avoided because of the risk of 
bradyarrhythmia or AV block [55]. By reducing heart rate and increasing dilation of coro-
nary vessels, calcium channel blockers, like the beta-blockers, reduce the ischemic burden in 
coronary artery disease, although due to decreased contractility they should be avoided in 
heart failure [85]. Nitrates cause vasodilation of both coronary arteries and veins that gives 
symptomatic relief of angina due to its active component nitric oxide. There are two types of 
nitrates: short-acting nitrates (sublingual nitroglycerin 0.3–0.6 mg, tablet or spray form, and 
isosorbide dinitrate 5 mg sublingually) that is used for acute angina. Long-acting nitrates 
are used for angina prophylaxis: isosorbide dinitrate (oral preparation), mononitrates, and 
transdermal nitroglycerin patches [55].
4.3. Treatment of heart failure
Treatment of heart failure includes pharmaceutical agents, comorbidities like anemia, 
implantable cardioverter defibrillators, cardiac resynchronization therapy, and mechanical 
circulatory support and transplant.
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4.3.1. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers
Renin-angiotensin-aldosterone system (RAAS) inhibition that is achieved by either angioten-
sin-converting enzyme inhibitors or angiotensin receptor blockers is an essential component 
of heart failure management. Both European and American guidelines for the management of 
heart failure recommend inhibition of the renin-angiotensin system for patients with chronic 
heart failure to reduce mortality and morbidity [86]. ARNi is a combination of an angiotensin 
receptor blocker and an inhibitor of neprilysin, which is an enzyme that breaks down vasoac-
tive peptides such as natriuretic peptides, adrenomedullin, and bradykinin and as a result 
brings about vasodilation. The first approved ARNi product was valsartan/sacubitril. ARNi 
should not be administered together with angiotensin-converting enzyme inhibitor, which 
has to be withdrawn [86].
4.3.2. Beta-blockers
Both in coronary artery disease and in heart failure, beta-blockers are a crucial part of therapy. 
Beta-blockers are useful independent of blood pressure levels in patients with heart failure and 
improve survival. Bisoprolol was shown to reduce mortality of patients with heart failure in 
the CIBIS-II trial [87]. The CIBIS-III trial showed non-inferiority for titration of bisoprolol before 
enalapril as compared to the reverse order [88]. Considering the beneficial and well-docu-
mented effect of beta-blockers in coronary artery disease, in ischemic cardiomyopathy, titration 
of beta-blockers first should be considered in hemodynamically stable patients. Metoprolol is 
also beneficial in heart failure and was in the MERIT-HF trial shown to improve survival by 
both preventing worsening of heart failure and decreasing risk of sudden cardiac death [89]. In 
the US Carvedilol HF trial, decreased risk of death was seen for carvedilol as well [90].
4.3.3. Selective aldosterone receptor antagonists
The selective aldosterone receptor antagonist group includes spironolactone and eplerenone. 
This class of medication exerts pharmacological effect by blocking the aldosterone recep-
tor; therefore, sodium reabsorption and diuresis are decreased, while potassium retention is 
increased. Consequently, they cause water loss and lower blood pressure. Spironolactone has 
been shown to decrease morbidity and mortality in symptomatic heart failure but is associated 
with antiandrogen side effects such as gynecomastia and disadvantageous mineral corticoid 
steroid effects [91]. Eplerenone has milder side effects and has shown at least similar beneficial 
effect on prognosis [92]. In symptomatic heart failure, a selective aldosterone receptor antago-
nist should be administered in addition to baseline therapy, if tolerated by the patient [6].
4.3.4. Digoxin
Digoxin, first isolated from the digitalis plant, has inotropic properties; it increases contrac-
tility and decreases heart rate. It is most commonly used in rate control of atrial fibrillation 
preferably in addition to beta-blockers. The role of digitalis in the treatment of patients with 
chronic heart failure is controversial, and its long-term effect on mortality remains unclear. 
Studies indicate that digoxin decreases the frequency of hospitalization and relives symptoms 
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of heart failure, but it has no effect on survival or mortality in individuals receiving angioten-
sin-converting enzyme inhibitors and diuretics [93].
4.3.5. Loop diuretics
By far the most commonly used loop diuretic is furosemide; alternative substances are 
bumetanide and torsemide. Blockage of sodium-potassium-chloride cotransporters results in 
increased excretion of sodium, chloride, and potassium and thereby increased diuresis [94]. 
This decreases the congestion induced by heart failure and therefore it can be useful for symp-
tomatic relief. High doses of loop diuretics have been linked to increased mortality; however, 
it is the patients with most severe heart failure and congestion that receive the highest doses. 
For stable patients enteral administration is used, while in cases of worsened heart failure 
with congestion, intravenous therapy is recommended [94].
4.3.6. Levosimendan
Levosimendan is an inodilator, with both vasodilator and positive inotropic properties. It 
increases calcium sensitization of troponin C and thus increases cardiac contractility [95]. It 
can be indicated in acutely decompensated patients with chronic heart failure due to systolic 
dysfunction of the left ventricle [95, 96]. Levosimendan is well tolerated in general but might 
have adverse effects such as hypotension, tachycardia, atrial fibrillation, hypokalemia, and 
headache [95]. Levosimendan has an active metabolite (OR-1896); due to this, effects such as 
improved hemodynamics and contractility can last for over 1 week. Infusions are adminis-
tered intermittently. Levosimendan infusions reduce symptoms, hospitalizations, and short-
term mortality [95].
4.3.7. Management of anemia
Anemia can mimic symptoms of heart failure such as dyspnea and tiredness. It also worsens 
prognosis and symptoms in heart failure. In the RED-HF trial darbepoetin alfa, an agent that 
binds to the erythropoietin receptor and thus stimulates formation of red blood cells did not 
decrease cardiovascular mortality in anemic heart failure patients; in fact it increased the risk 
of stroke [97]. Intravenous iron on the other hand has been shown to decrease symptoms and 
improve quality of life, and enteral iron substitution is associated with gastrointestinal side 
effects that might be exacerbated in heart failure where gastrointestinal swelling and malabsorp-
tion are common [98]. Anemia might worsen ischemia in coronary artery disease, the underly-
ing cause of ischemic cardiomyopathy, and thus extra care is warranted in this group of patients.
4.3.8. Implantable cardioverter defibrillators
Implantable cardioverter defibrillators (ICDs) effectively not only abort ventricular arrhythmias 
by either antitachycardia pacing or cardioversion but also provide protection against bradycar-
dia. In heart failure, a major cause of death is due to sudden arrhythmic events. Notably, the pro-
portion of sudden cardiac death is higher in patients with NYHA II than NYHA III. Therefore, 
even patients with mild heart failure symptoms need to be considered for an ICD as primary 
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prevention. Antiarrhythmic drugs, including amiodarone, might reduce the risk of tachyar-
rhythmia, but they do not reduce overall mortality and may even increase it. In survivors of 
cardiac arrest, ICD is recommended as secondary prevention. Patients who have documented 
ventricular tachycardia with hemodynamic compromise have a secondary prevention indica-
tion for ICD for protection from sudden cardiac death [99–102]. Primary prevention indication 
for ICD should be considered in patients who never experienced a ventricular arrhythmia, 
with ejection fraction below 35% despite at least 3 months of optimal pharmacological therapy, 
NYHA functional classes II–III, and at least an estimated survival above 1 year. Two randomized 
controlled trials showed no benefit in patients who had an ICD the first 40 days after myocar-
dial infarction [103, 104]. If the patient is considered at high risk, during this period a wearable 
defibrillator is an option [105, 106]. Before offering the patient an ICD, the physician should inte-
grate information about comorbidity and life expectancy; if it is estimated to be less than 1 year 
including patients with NYHA IV despite pharmacological optimization, ICD is not indicated, 
but the patient may be reevaluated if improvement occurs. For the group of patients with mild 
heart failure (NYHA II), an ICD saves one life per year for every 50 patients. Ischemic cardiomy-
opathy patients have higher risk of sudden death, and the benefit in that group is believed to be 
higher [107]. In elective replacement of an ischemic cardiomyopathy device, careful judgment is 
warranted including reevaluation of risk [108–112]. Subcutaneous ICD (S-ICD) is an alternative 
in selected cases where risk of infection is high or vascular access is difficult and when there 
is no need of pacing or expected need of antitachycardia pacing. In general 20% of ICD leads 
fail over a period of 10 years; therefore, S-ICD may be more advantageous in cases of long life 
expectancy [113, 114].
4.3.9. Cardiac resynchronization therapy
Cardiac resynchronization therapy (CRT), which can be used either with a pacemaker (CRT-P) 
or with an ICD (CRT-D), reduces morbidity and mortality and improves health-related qual-
ity of life in selected patients who fulfill certain criteria [115]. The principle of these devices is 
to use a pacing system that is biventricular to decrease dyssynchrony and thus heart failure, 
in patients with heart failure, reduced ejection fraction, and a bundle branch block [116].
According to ESC guidelines from 2013 regarding the indications of CRT in patients with 
heart failure and sinus rhythm:
• Left bundle branch block with QRS duration >150 ms. CRT is recommended in chronic 
heart failure patients with left ventricular ejection fraction ≤35% who remain in NYHA 
functional classes II, III, and ambulatory IV despite adequate medical treatment (recom-
mendation class I, level of evidence A).
• Left bundle branch block with QRS duration 120–150 ms. CRT is recommended in chronic 
heart failure patients with left ventricular ejection fraction ≤35% who remain in NYHA 
functional classes II, III, and ambulatory IV despite adequate medical treatment (recom-
mendation class I, level of evidence B).
• Non-left bundle branch block with QRS duration >150 ms. CRT should be considered in 
chronic heart failure patients with left ventricular ejection fraction ≤35% who remain in 
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NYHA functional classes II, III, and ambulatory IV despite adequate medical treatment 
(recommendation class IIa, level of evidence B).
• Non-left bundle branch block with QRS duration 120–150 ms. CRT may be considered in 
chronic heart failure patients with left ventricular ejection fraction ≤35% who remain in 
NYHA functional classes II, III, and ambulatory IV despite adequate medical treatment 
(recommendation class IIb, level of evidence B).
• CRT in patients with chronic heart failure with QRS duration <120 ms is not recommended 
(recommendation class III, level of evidence B) [117].
In clinical practice it has been revealed that CRT in patients with severe heart failure has positive 
effects on symptoms and exercise tolerance. Furthermore, it improved quality of life and mini-
mized the need for rehospitalization. However, some patients are nonresponders and receive 
little or no benefit from CRT. The level of ejection fraction in the trials varies: RAFT and MADIT-
CRT used 30% as a cutoff [118, 119]. REVERSE used 40% and BLOCK-HF 50% [118, 120–122]. The 
QRS width is important in selecting patients. None of the landmark trial selected patients based 
on sex, QRS morphology, or ischemic vs. nonischemic subgroups. It is not clear if CRT itself 
reduces the need for ICD or if the improvement of heart failure may expose the patient to a longer 
period of risk for sudden death. Imaging tests with regard to dyssynchrony are not part of guide-
lines in selecting patients for CRT [123]. When there is an extensive myocardial scar, the improve-
ment in ejection fraction will be less, and the optimal placement of the left ventricular lead will be 
more difficult to gain acceptable pacing thresholds without phrenic nerve stimulation.
4.3.10. Mechanical circulatory support and transplant
In patients who do not stabilize with optimal pharmacological therapy, the need for further 
therapeutic options including mechanical assists should be addressed. In cardiogenic shock, 
extracorporeal support like Impella™ can be used for temporary bridging. When long-term 
mechanical assist is indicated, left ventricular assist device can be used for recovery or more 
often as destination therapy if transplant is not possible. In the meantime, extracorporeal 
membrane oxygenation (ECMO) may be used to support patients with heart failure (left or 
biventricular failure) until a decision about a permanent solution is taken. In a randomized 
trial on high-risk percutaneous coronary intervention in patients with impaired left ventricu-
lar function, the 30-day cumulative incidence of major adverse events was not different for 
patients with intra-aortic balloon pump as compared to left ventricular assist device [124]. 
Due to lack of heart donors, the left ventricular assist device as a destination therapy has been 
advocated. The survival rates after 3 years in those receiving the latest continuous flow devices 
are at least as good as in transplanted patients, but long-term survival is unknown [125].
5. Conclusions
Ischemic cardiomyopathy, which is commonly encountered as an underlying cause of heart 
failure, warrants qualified management to improve survival. This includes thorough evaluation 
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and optimal pharmaceutical treatment, device therapy with cardiac resynchronization therapy 
with/without an implantable cardioverter defibrillator, and mechanical support as bridging or 
destination therapy in end-stage disease. From a general perspective, it is crucial to reduce risk 
factors for coronary artery disease to prevent ischemic cardiomyopathy.
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